Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,737 Cr
verified against source
Revenue YoY
10.7%
reported change
EBITDA
₹828 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Alkem delivered a stable Q3 with total revenue of ₹3,737 crore (+10.7% YoY) and EBITDA margin of 22.2%. Domestic business grew 5.5% reported but ~10% on a normalized basis, driven by strong chronic portfolio and market share gains across six therapies. International sales surged 26.6% YoY to ₹1,216 crore. The highlight was the announcement of a 55% stake acquisition in Occlutech, a structural heart medtech company, for ~₹1,100 crore, with plans to scale revenue to ₹1,000 crore in 3-5 years and improve EBITDA margins from 4% to 25%. Management reiterated full-year guidance and bullish outlook. Key risk: MIP on penicillin derivatives could impact gross margins by 50-100 bps, though inventory and pricing actions may mitigate.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects domestic business to continue growing 100-150 bps above IPM growth, with FY26 ending at ~10% growth.
- Occlutech's EBITDA margin is expected to improve from current ~4% to 25% in 3-5 years, driven by operating leverage and product mix.
- Occlutech is expected to grow at 14% CAGR over the next 5 years, reaching ~₹780 crore, excluding new products.
- Denosumab US launch expected by end of FY26, pending FDA inspection and litigation resolution.
Risks flagged
- The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.
- Occlutech operates in a different segment (medtech) with complex regulatory and manufacturing requirements; integration and scaling may face challenges.
- US entry for denosumab is subject to ongoing litigation with Amgen, which could delay launch beyond FY26.
- Trade generic business has been flat to low single-digit growth due to competitive pressures and conscious margin protection, potentially dragging overall domestic growth.
Key quotes
- I think after biotech this could be one very valuable subsidiary that we will create in the long term.
- We are very clear about it. We will run it independently and it is different but it falls under healthcare.
- We are already EBITDA positive in the present year and our estimate is to have 10% EBITDA by FY27 which will take us to around 23 to 24% in 3 years time.
Research modules